An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001
- Registry ID
- EUCTR2006-006755-12
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Janssen Oncology, Inc.
- Start date
- 2007-01-09
- Completion date
- 2012-09-04
- Last update
- 2026-08-16
Conditions
- Hormone refractory prostate cancer
Summary
To provide access to CB7630 for patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such a treatment.
Locations
View on source registry